Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. The myeloma panelists are talking to Dr. Ola Landgren, a lead researcher in the field, on what MRD testing could mean to your treatment, and about how MRD testing could become a new and earlier end-point in myeloma treatment.